Related Experiment Video
Updated: Mar 19, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Statins and Their Effect on PCSK9-Impact and Clinical Relevance
Beth A Taylor1,2,3, Paul D Thompson4,5
1Department of Kinesiology, University of Connecticut, Gampel Pavilion Room 207, 2095 Hillside Rd, U-1110, Storrs, CT, 06269-1110, USA. Beth.Taylor@uconn.edu.
Purpose Of Review:
To review the interactions between statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.
Recent Findings:
Statins are highly effective for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular disease (CVD). However, statins also raise levels of PCSK9, a protein that increases circulating LDL-C levels by increasing LDL-C receptor degradation. Increases in PCSK9 levels also reduce the LDL-C response to statin therapy. The interactions between statins, PCSK9, LDL-C, and cardiovascular risk are multifaceted and are influenced by genetic, lifestyle, and environmental factors as well as lipid-lowering therapies.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease IV: Preventive Measures
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Cholesterol: Significance and Regulation
Considering cholesterol and...

